AstraZeneca's Enhertu wins EU nod for HER2-positive solid tumors (revised)
- Posted on July 1, 2026
- By Bing News
- 0 Views
- 1 min read
AstraZeneca's Enhertu wins EU nod for HER2-positive solid tumors (revised)
AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the European Commission (EC) has approved their blockbuster antibody-drug conjugate (ADC), Enhertu, as a monotherapy for previously treated HER2-positive solid tumors. The approval marks Enhertu's sixth indication in the European Union (EU). Separately, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of...
